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Abstract
           
Objective: To review: 1) Pathophysiology of postoperative atrial fibrillation (POAF); 2) Risk 
factors for POAF; 3) Prophylaxis of POAF; 4) Treatment of POAF; and 5) Future directions.  
Methods: We searched the Medline database for articles published between January, 1966 to 
September, 2008. We used the following keywords: Atrial fibrillation, Postoperative atrial 
fibrillation, coronary Artery Bypass, and antiarrhythmic agents. Additionally, we searched 
references from all relevant articles.                                                                               
Conclusions: POAF occurs in 25-60% of patients depending on the type of cardiac surgery 
performed. POAF generally occurs on postoperative day 2 or 3. POAF is associated with an 
increased risk of morbidity and mortality, and longer hospital stay. Prophylactic treatments 
reduce the likelihood of POAF. In patients who experience POAF, rhythm strategies should be 
used in those who are symptomatic and hemodynamically unstable. All other patients should be 
managed with rate strategies.                                                                                     
Key   Words:  Atrial   fibrillation,   postoperative   atrial   fibrillation,   coronary   artery   bypass, 
antiarrhythmic agents.
Introduction
            An estimated 800,000 cardiac surgeries are annually performed in the United States1. 
The most common complication after cardiac surgery is atrial fibrillation (AF) and/or atrial 
flutter (AFL). Approximately 25-40% of patients have postoperative AF (POAF) after coronary 
artery bypass graft (CABG) and 50-60% after valvular surgery. The incidence of POAF is the 
highest in patients who have CABG and concomitant valve surgery, reaching 62%. The lowest 
incidence of POAF is seen in patients after heart transplant. The increasing incidence of POAF 
is most likely a result of the greater number of older patients having cardiac surgeries2,3.  
            POAF episodes predominantly occur on postoperative days 2-3 and 70% of all episodes 
occur within the first 4 postoperative days. Recurrence of POAF most often occurs on 
postoperative day 3. Approximately 60% of all recurrences occur within two days of the initial 
episode of POAF. Nevertheless, POAF can occur at anytime after surgery. The main cause of 
hospital readmission after early hospital discharge following cardiac surgery is AF2-5.                 
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            While POAF is often considered both transient and "benign", it has been associated with 
congestive heart failure (CHF), three-fold higher  risk of postoperative stroke and renal 
insufficiency2,3.  Moreover, POAF results in longer ICU and hospital stays by an average of 1 to 
4 days  POAF is associated with increased cost per patient ranging from $5-20,000 dollars2-4.  
The financial burden of POAF exceeds $1 billion dollars annually in the United States3,4. For 
these reasons, several trials have been conducted in an attempt to decipher the various aspects of 
POAF.  This paper will review the relevant literature concerning: 1) Pathophysiology of POAF; 
2) Risk factors for POAF; 3) Prophylaxis of POAF; 4) Treatment of POAF; and 5) Future 
directions   in   POAF.                                                                                        
Pathophysiology of Postoperative Atrial Fibrillation   
               At present, it is hypothesized that AF is initiated by ectopic beats predominantly 
originating from the thoracic veins. Reentry, increased automaticity, and triggered activity have 
all been postulated as mechanisms that can cause arrhythmogenesis from the pulmonary veins. 
Some studies have indicated that an electrophysiological substrate within the pulmonary veins 
allows reentry due to heterogeneous refractory periods and decremental conduction. The 
pathophysiology of AF involved reentry of multiple wavelets which circulate around the atrium. 
Other studies have indicated that automaticity is the potential mechanism because of dependence 
on adrenergic stimuli and the presence of dissociated autonomic rhythms within the pulmonary 
veins that are electrically isolated from the left atrium. It has been noted that soon after 
disconnection of the pulmonary veins from the left atrium, the cycle length of electrical activity 
within the pulmonary veins becomes longer, and eventually the tachycardia resolves suggesting 
that the muscle sleeves surrounding the pulmonary veins depend upon electrical input from the 
left atrium to maintain pulmonary vein tachycardia. Dependence on an external input and the 
response to calcium channel blockers are in accordance to triggered activity. It is likely that the 
mechanism   responsible   for   the   initiation   and   perpetuation   of   AF   is   multifactorial6.  
            While ectopic beats arising from the pulmonary veins have often been the culprit for 
initiation of paroxysmal AF in non-surgical patients, the exact mechanism of AF after cardiac 
surgery has yet to be determined. At present, there is not a definitive explanation as to why some 
individuals develop POAF and others do not. Nevertheless, most episodes are probably initiated 
by triggers such as premature atrial contractions in patients with a conducive atrial substrate.
            Several studies have suggested that a heightened sympathetic response predisposes a 
patient to developing AF. However, it is interesting to note that the highest sympathetic levels 
are found 24 hours postoperatively and that most episodes of POAF develop on day 2 or 32,6,7. 
Furthermore, atrial refractoriness is dependent upon both sympathetic and parasympathetic 
contributions; therefore, the likelihood that a single culprit is responsible for POAF is low. 
Enhanced vagal tone has also been found in nonsurgical patients who have AF. Either 
heightened sympathetic or vagal tone may increase the likelihood of AF6,7.                        
               The association between AF and inflammation was first observed by Frustaci who 
demonstrated that the atria of patients with lone AF had a higher prevalence of inflammatory 
infiltrates, myocyte necrosis, and fibrosis in comparison to patients without AF8. Since then, 
several studies have explored the role of inflammation in AF; however, there is still some debate 
as to whether inflammation causes AF. Rapid atrial activation causes an accumulation of 
calcium in atrial myocytes. As a result of the increased levels of intracellular calcium, there is a 
reduction of the inward L-type Ca2+  current. This results in both a shorter action potential 
duration and effective refractory period, thereby creating a favorable environment for the 
initiation and perpetuation of AF. In some cases the Ca2+  can cause cell apoptosis and 
subsequent inflammatory response and may contribute to structural remodeling and ultimately 
persistence of AF (Figure 1)9.  
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8 (4): 281-291 (2008)Dimpi Patel, Marc A Gillinov, Andrea Natale,                                                                       283 
“Atrial Fibrillation after Cardiac Surgery:  Where are we now?”
Figure 1:   The potential  role of inflammation and  oxidative stress  in atrial fibrillation-induced  electrical 
remodeling.   Ical-L-type   Ca2+  current;   ADP-action   potential   duration;   AERP-atrial   refractory   period;   CV-
conduction velocity.  Reproduced with permission from Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. 
Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Reproduced 
with permission from Med Sci Monit. 2003;9:RA225-9.
               C-reactive protein (CRP) is a highly sensitive systemic marker for inflammation. 
Elevated CRP levels have been shown to be a strong predictor of AF in both surgical and non-
surgical patients. It has been shown that on postoperative day 2-3 the CRP levels are the highest, 
corresponding to the day of highest incidence of POAF. Moreover patients with a higher 
baseline CRP level are more likely to develop POAF after on and off pump surgery10-12.   
            Oxidative damage has been found in the atrial myocardium of patients with chronic AF. 
The mechanism of oxidative damage in atrial myofibrils is mediated through the action of 
hydroxyl   radicals   and   peroxynitrite   leading   to   the   formation   of   protein   carbonyls   and 
nitrotyrosines. Oxidative damage affects the myofibrillar creatine kinase which is an important 
controller of myocyte contractility which may contribute to severe contractile dysfunction and 
structural and electrophysiological remodeling11. A study that evaluated the effect of oral 
vitamin C on rapid atrial pacing induced atrial electrical remodeling in dogs provided further 
evidence supporting the role of oxidative stress in AF. In this study vitamin C was shown to 
eliminate ERP shortening. Additionally, vitamin C also inhibited the formation of nitrotyosine 
formation in atrial tissue, pointing to effective scavenging of peroxynitrite. Furthermore, this 
study also assessed whether prophylactic vitamin C reduced the incidence of POAF in patients 
who underwent CABG. This analysis suggested that in patients receiving prophylactic vitamin C 
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the incidence of POAF was 34.9% in comparison to 16.3% in those that did not receive vitamin 
C. However, this was not confirmed by a prospective randomized study. It is speculated that 
vitamin C eliminates Ca2+ accumulation through scavenging reactive oxygen species that affect 
atrial proteins12. (Figure 1)                                                                                                 
Risk   factors                                                                                    
            Risk factors associated with POAF have traditionally been stratified as preoperative, 
intraoperative, and postoperative.  Several studies have identified characteristics that predispose 
a patient to POAF.  Nevertheless, the findings are often inconsistent between studies. Many prior 
studies have been conducted at a single center which limits the universality of their findings.       
Inconsistencies can be attributed to the fact that patient characteristics varied between studies, 
utilization of a non-standardized method of identifying and defining arrhythmia, and small 
population sizes. In the future, if a uniform risk list can be accrued, it will provide insight into 
the pathophysiology of POAF, allow for prevention strategies, and help select patients who will 
benefit the most from such strategies2-4. (Figure 2)                                                         
Figure 2:  Risk is determined by assigning points from the points scale for each of the predictors listed and then 
plotting the total points received against the risk score at the bottom of the nomogram. For example, 50 points 
predicts a risk of postoperative atrial fibrillation of 88%.  ACE indicates angiotensin-converting enzyme; COPD, 
Chronic obstructive pulmonary disease, and NSAIDs, nonsteriodal anti-inflammatory drugs.   Reproduced with 
permission from Mathew JP, Parks R, Savino JS et al. Atrial fibrillation following coronary artery bypass graft 
surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research 
Group. JAMA 1996; 276:300-306.
Preoperative
            The incidence of AF increases with increasing age in the general population. Similarly, 
increased age consistently predicts a greater likelihood of POAF. With each decade of patient 
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age, the incidence of PAOF increases by 75%. Atrial dilation, fibrosis and lipid deposits increase 
with age along with non-uniform anisotropic conduction. As a result of these histological 
changes, electrical conduction within the atria slows thus providing a substrate for arrhythmias. 
It has been hypothesized that increased amount of connective tissue and the resulting non-
uniform anistrophic conduction peaks at 80 years of age and then plateaus. At present, few 
cardiac surgery patients are over 80 years old; however, the age of individuals undergoing 
cardiac surgery is increasing. The changes in the atrial substrate may not only be associated with 
the CABG surgery itself because a higher incidence of atrial fibrillation in older patients is seen 
in the non-surgical Framingham population2,3,13.                                                                            
            Some studies have found an increased incidence of POAF in males, while other studies 
have reported no gender impact. The increased incidence of POAF in males versus females can 
be explained by differences in ion channel expression and by hormonal effects on autonomic 
tone.  
            Studies have shown that a prior history of AF increases the likelihood of developing 
postoperative AF. Mathew et al showed that 53% of patients with a prior history of AF had 
POAF2.   Recurrence of AF can be due to alterations in the atrial substrate during surgery. 
However, it is more likely that the reason for recurrence is that preoperatively the patient has a 
diseased myocardium and with the surgery the patient is re-exposed to an environment that 
triggered the initial AF.                                                                                                  
            Recently, Osranek et al found that left atrial volume is a strong and independent predictor 
of POAF. Patients with a left atrial volume greater than 32 ml/m2  had an almost a 5 fold greater 
risk   of   POAF14.                                                                                            
            Several studies have found that prolonged preoperative signal averaged P-wave duration 
is a positive predictor for postoperative AF. Another study found that on surface ECG a 
prolonged PR interval or a prolonged P-wave duration identified patients with a higher risk for 
developing postoperative atrial fibrillation15,16.                                                                    
            Several studies have found that discontinuation of beta adrenergic antagonists prior to 
surgery increases risk of POAF Mathew et al have shown that preoperative withdrawal of either 
B-receptor antagonists or ACE inhibitors increases the likelihood of developing POAF to 50% 
and   46%,   respectively2.                                                                    
            Other patient characteristics associated with POAF include: COPD, CHF, rheumatic 
heart   disease,   right   coronary   artery   stenosis,   atrial   ischemia,   preoperative   digoxin,   left 
ventricular hypertrophy, elevation in left ventricular end-diastolic pressure prior to surgery, 
obstructive lung disease, and hypothyroidism2-4.                                                   
Intraoperative
            Cardiopulmonary bypass deprives the heart of blood flow and thus could result in atrial 
injury and postoperative arrhythmias. Some studies have demonstrated that long procedure times 
can increase the likelihood of atrial fibrillation and that aortic-cross clamp time correlates with 
POAF17-19. Inadequate atrial myocardial protection during aortic cross clamping results in atrial 
ischemia triggering POAF. A study evaluated whether myocardial ischemic conditioning during 
surgery can prevent POAF. In this study 85 patients having on pump CABG were put into a 
control group or a group receiving 2 minutes of ischemic preconditioning achieved by temporary 
aortic   cross   clamping.   The   incidence   of   postoperative   AF   was   lower   in   the   ischemic 
preconditioning group (21.4%) than in the control group (46.5% P=.015)18.                  
            The location of venous cannulation has also been associated with POAF. Pulmonary vein 
and bicaval cannulation had also been associated with increased risk for POAF in some 
studies19. Furthermore, an elevation in intratrial pressure can increase the rate of waves coming 
from ectopic foci in the pulmonary veins in a stretch induced AF model20.                    
               Systemic hypothermia reduces metabolic demands of the ventricles and provides 
myocardial, cerebral, and somatic protection during the procedure. Traditional hypothermic 
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cardioplegia does not adequately cool the atria or ensure complete electrical arrest in the atria. 
The use of warm cardioplegia is becoming common. However, studies of myocardial protection 
have not found different rates of postoperative atrial tachyarrhythmia associated with the various 
techniques17,21.  
            Valve surgery is associated with an increased risk of POAF. The incidence of atrial 
fibrillation   after   valve   surgery   typically   exceeds   that   in   patients   undergoing   coronary 
revascularization alone, with the greater susceptibility believed to result from structural and 
hemodynamic   abnormalities   such   as   left   atrial   enlargement,   pathological   changes   from 
rheumatic heart disease, increased left atrial pressure and surgical trauma17.                  
Postoperative 
               Pneumonia,   chronic   obstructive   lung   disease,   hypomagnesaemia   and   prolonged 
ventilation are associated with atrial fibrillation after cardiac surgery. The need for postoperative 
atrial pacing is independently associated with atrial fibrillation. Moreover, it may also indicate 
underlying   sinus-node   dysfunction.                                                              
Prophylaxis of Postoperative Atrial Fibrillation                                            
β-receptor antagonists (Vaughan-Williams class II)                                                                     
            β-receptor antagonists (Vaughan-Williams class II) reduce the likelihood of developing 
POAF in many studies. Increased sympathetic tone may predispose a patient to POAF and β-
receptor antagonists target this pathway. A meta-analysis of 27 studies evaluating 3,840 patients 
compared β-receptor antagonist versus placebo for POAF prevention. (Figure 3).  There was a 
14% reduction in incidence POAF between the control group and β-receptor antagonist group 
P<0.00001.   Furthermore, patients receiving long-term β -receptor antagonist therapy prior to 
cardiac surgery and who do not continue β-receptor antagonist postoperatively have a higher 
incidence of POAF. Therefore, unless specifically contradicted, reinitiation  of β-receptor 
antagonists should not be postponed. Interestingly, two  β-receptor antagonist trials including 
1200 patients showed no significant reduction in the length of hospital stay (-0.66 days; 95% CI, 
-2.04 to 0.72) (Figure 4). Trials have also compared β-receptor antagonists to digitalis, 
propafenone, and diltaziem. The findings from these studies were not conclusive due to  small 
sample size2,22.
Sotalol (Vaughan-Williams Class III agents)                                                                 
            Sotalol (Vaughan-Williams Class III agents) has a combination of β-receptor antagonist 
and potassium channel antagonist properties. A meta-analysis including eight randomized trials 
with 1294 patients compared the efficacy of sotalol versus placebo. The incidence of POAF in 
the placebo group was 37% and decreased to 17% in the sotalol group P<0.00001. However, 5 
trials including 808 patients found that sotalol does not have any significant effect on the length 
of hospital stay (-.40 days, 95%CI, -0.87 to 0.08) (Figure 4).  Some limitations of the sotalol 
trials include: small subject size, exclusion of the sickest patients, and open label trials that 
might   bias   the   results2,16.                                                                        
               Since both sotalol and β-receptor antagonist are tantamount in terms of patient 
tolerability and side effects, a crucial issue is whether sotalol provides additional antiarrhythmic 
benefits for POAF offsetting the risk of associated proarrhythmia. Four trials compared sotatol 
with β-receptor antagonist and included a total of 900 patients. Two of the four trials showed 
statistically significant reduction in POAF in patients treated with sotalol and the larger of the 
two did not show significant reduction in POAF. When these four trials were directly compared 
via meta analysis, it was found that patients in the sotalol group had a 12% occurrence of POAF 
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versus 22% in the β-receptor antagonist group (OR, 0.50; 95% CI, 0.34 to 0.74). Nevertheless 
while sotalol appears to be more effective than β-receptor antagonist these trials are relatively 
small2,22.
Figure 3: Beta blockers versus placebo or no treatment for the prevention of AF.   Test for heterogeneity 
P=0.00001.  Test for overall effect P<0.00001.  Published with permission from Crystal E, Connolly S, Sleik K et 
al.  Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery:  A Meta-
Analysis.  Circulation 2002;106:75-80.
Amiodarone
            Amiodarone prophylaxis for POAF has been evaluated in 10 trials, including a total of 
1,699 patients. Four trials found that amiodarone significantly reduced POAF. Nine trials 
including 1384 patients were compared via meta analysis. There was a 22.5% occurrence of 
POAF in the amiodarone group versus 37% in the control group P<0.00001. Five amiodarone 
trials including 944 patients (68% on amiodarone) reported a significant reduction in the length 
of hospital stay by 0.91 days (95% CI, -1.59 to -0.24) (Figure 4). Since amiodarone is 
associated with little risk of proarrhythmia, it can be used in patients with structurally abnormal 
hearts; however, only oral amiodarone has been shown to reduce POAF, and this requires a 7 
day loading dose, which is not always feasible2,22.                                                                       
Calcium   Channel   Blockers
            There have been four trials conducted that evaluate the efficacy of calcium channel 
blockers including a total of 541 patients. Calcium channel blockers did not significantly reduce 
POAF in any of these trials2,22.                                                                                       
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Magnesium
            There have been 14 trials including 1,853 patients that evaluated whether magnesium 
chloride or magnesium sulfate supplementation reduced the occurrence of POAF. Only 1 of 
these 14 trials demonstrated a statistically significant reduction in POAF.  Although magnesium 
most likely does not offer prophylaxis against POAF, serum magnesium levels should be 
regulated2,16.  
Digitalis
            Ten studies including 1,401 patients have been performed assessing the efficacy of 
digitalis for the prophylaxis of POAF. The limitations of some of these trials include non-
randomization and the fact that β-receptor antagonists were withdrawn postoperatively. Due to 
the limitations of these trials and the availability of better therapies, digitalis should not be used 
solely for prophylaxis of POAF2,22.                                                                                   
Atrial   Pacing                                                                                  
            Thirteen trials have been conducted to assess whether prophylactic pacing after cardiac 
surgery is able to prevent POAF. Overall, studies with prophylactic right atrial pacing and 
prophylactic left atrial pacing have been inconclusive. Bi-atrial pacing was found to reduce the 
length of hospital stay by 1.54 days (95%Ci -2.85 to 0.24) (Figure 4). Of the nine trials that 
assessed biatrial pacing versus control, POAF was reduced in seven trials. The inability to obtain 
consistent atrial capture throughout the postoperative phase appears to be an important limitation 
of this therapeutic modality. Limitations of these thirteen trials include different exclusion 
criteria,   concomitant   β-receptor   antagonist,   and   different   techniques   for   recording   AF 
episodes2,22.
Figure 4: Effect of treatment on the length of hospital stay. Published with permission from Crystal E, Connolly S, 
Sleik K et al.   Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart 
Surgery:  A Meta-Analysis. Circulation 2002;106:75-80.
            Meta analysis has shown that the incidence of POAF can be reduced by prophylactic 
therapy thus decreasing the length of hospital stay, risk of stroke, morbidity, mortality, and the 
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cost of care. The ACC guidelines recommend β-receptor antagonists be used as first-line 
prevention of POAF and that sotalol and amiodarone be used as second-line prevention22,23.      
            AF prophylaxis reduces the length of hospital stay by 1.5 days. While this does not seem 
like a substantial reduction in length of hospitalization, only 50% of patients will experience 
POAF, thus, in order to detect a significant reduction in the length of hospital stay in an overall 
population the effect must be very large. Furthermore, with the use of prophylactic therapy there 
is a risk of side effects which influence the length of hospital stay. Regardless, even a small 
reduction in hospital stay can result in a considerable cost benefit especially since β-receptor 
antagonists   are   inexpensive2,22.                                                                        
               A meta-analysis including 2877 patients indicates that POAF prophylaxis has no 
statistically significant benefit in terms of stroke prevention22. The rationale is that most patients 
after cardiac surgery do not have POAF. Furthermore, if the likelihood of stroke with POAF is 
similar to that of chronic AF which is 5% per year, the risk of stroke during a 1 day episode of 
POAF would be less than 1 in 1000.                                                                     
    
Treatment   of   POAF                                                                                      
            Much like non-surgical AF, the therapeutic issues in POAF center on restoring and 
maintaining   sinus   rhythm,   controlling   cardiac   rate   and   preventing   thromboembolic 
complications. Restoration of sinus rhythm should be pursued in patients with POAF who are 
hemodynamically unstable, symptomatic, or cannot tolerate anticoagulation. Rate management 
is   appropriate   for   all   other   patients24.                                                              
Future directions in the treatment of POAF                                                                       
            New drugs such as a class III potassium channel blockers that block the rapid and slow 
I(kr) currents are promising. Trials are also under way assessing dronedarone, a drug that is 
similar   to   amiodarone25.                                                                                   
            The MAZE procedure is complicated and difficult to perform, therefore, it is not likely 
that it will become a mainstay for the management of POAF. Alternative approaches have 
become available and are increasingly performed. Atrial specific drugs, a better understanding of 
inflammation and prophylactic procedures in high risk patients may help limit health care costs, 
morbidity and mortality associated with the development of POAF.  
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